EUCTR2012-001609-25-IT进行中(未招募)不适用
A randomizEd, double-masked, placebo-controlled study of the safetY and Efficacy of GevokizUmAb in the tReatment of subjects with noninfectious intermeDiate, posterior, or pan- uveitis currently controlled with systemic treatment. The EYEGUARD-C Study. - The EYEGUARD-C Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- XOMA
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosis of non-infectious intermediate, posterior, or pan-uveitis in at least one eye fulfilling the International Study Group Classification Criteria (SUN criteria) of intermediate, posterior, or pan- uveitis confirmed by documented medical history; - Controlled uveitic disease in both eyes, defined by no active inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber cell grade < or = 0.5+ according to SUN criteria, Vitrous Haze grade < or = 0.5+ according to the SUN/NEI Scoring for Vitrous Haze; - Best Corrected Visual Acuity of 35 letters or more in both eyes; - Patients with a stable dose of oral corticosteroids, alone or in combination with selected stable immunosuppressive therapy; - Male or female, age =18 (or legal age of majority in the country) at selection; - For subjects with reproductive potential, a willingness to use highly effective contraceptive measures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- Infectious uveitis and masquerade syndromes ; - Isolated anterior uveitis; - Best corrected visual acuity < 35 letters in both eyes or monocular vision; - Presence of severe cataract or severe posterior capsular opacification; - Contraindication to mydriatics or presence of posterior synechiae, in either eye; - Active TB disease; - History of severe allergic or anaphylactic reactions to monoclonal antibodies; - History of malignancy within 5 years prior to Selection; - Infectious disease; - Known immunodeficiency; - Pregnancy, breastfeeding or possibility to become pregnant during the study.
研究者
相似试验
已完成
2 期
A study of DE-127 ophthalmic solution in subjects with myopia - A Phase II/IIIMyopiaJPRN-jRCT2080224816Santen Pharmaceutical co.,Ltd288
进行中(未招募)
1 期
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisEUCTR2012-001125-27-GBInstitut de Recherches Internationales Servier84
进行中(未招募)
不适用
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisEUCTR2012-001125-27-GRInstitut de Recherches Internationales Servier110
进行中(未招募)
不适用
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisBehçet?s disease uveitisMedDRA version: 14.1Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004870EUCTR2012-001125-27-ESaboratorios Servier S.L.110
进行中(未招募)
1 期
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisBehçet’s disease uveitisMedDRA version: 18.0Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004866EUCTR2012-001125-27-PTInstitut de Recherches Internationales Servier44
